MRSN Key Statistics, Chart & Performance
The current stock price of MRSN is 27.775 USD. In the past month the price increased by 245.46%. In the past year, price decreased by -56.09%.
MRSN Latest News, Press Relases and Analysis
MRSN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About MRSN
Company Profile
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Company Info
MERSANA THERAPEUTICS INC
840 Memorial Dr
Cambridge MASSACHUSETTS 02139 US
CEO: Anna Protopapas
Employees: 102
Phone: 16174980020
MERSANA THERAPEUTICS INC / MRSN FAQ
What does MRSN do?
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Can you provide the latest stock price for MERSANA THERAPEUTICS INC?
The current stock price of MRSN is 27.775 USD. The price increased by 1.11% in the last trading session.
Does MERSANA THERAPEUTICS INC pay dividends?
MRSN does not pay a dividend.
How is the ChartMill rating for MERSANA THERAPEUTICS INC?
MRSN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for MRSN stock?
14 analysts have analysed MRSN and the average price target is 33.86 USD. This implies a price increase of 21.92% is expected in the next year compared to the current price of 27.775.
What is the GICS sector and industry of MRSN stock?
MERSANA THERAPEUTICS INC (MRSN) operates in the Health Care sector and the Biotechnology industry.
Can you provide the short interest for MRSN stock?
The outstanding short interest for MERSANA THERAPEUTICS INC (MRSN) is 6.11% of its float.
MRSN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MRSN. When comparing the yearly performance of all stocks, MRSN is one of the better performing stocks in the market, outperforming 97.88% of all stocks.
MRSN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MRSN. MRSN may be in some trouble as it scores bad on both profitability and health.
MRSN Financial Highlights
Over the last trailing twelve months MRSN reported a non-GAAP Earnings per Share(EPS) of -13.88. The EPS increased by 8.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.8% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRSN Forecast & Estimates
14 analysts have analysed MRSN and the average price target is 33.86 USD. This implies a price increase of 21.92% is expected in the next year compared to the current price of 27.775.
For the next year, analysts expect an EPS growth of 39.26% and a revenue growth -24.85% for MRSN